Helius Medical Technologies, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
HSDT Nasdaq 3840 heliusmedical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Helius Medical Technologies, Inc.

Helius Medical Technologies Announces Reverse Stock Split - Jun 27th, 2025 6:30 am
Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device - Jun 16th, 2025 5:00 am
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting - Jun 12th, 2025 5:00 am
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device - Jun 11th, 2025 5:00 am
Top Midday Decliners - Jun 5th, 2025 12:21 pm
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering - Jun 4th, 2025 7:12 pm
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria - Jun 4th, 2025 5:00 am
Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting - May 20th, 2025 5:00 am
Helius joins BCI landscape with new subsidiary - Mar 14th, 2025 10:25 am
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary - Mar 13th, 2025 5:00 am
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - Mar 11th, 2025 5:00 am
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study - Jan 22nd, 2025 5:00 am
Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market - Jan 21st, 2025 6:00 pm
Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target - Jan 21st, 2025 5:00 am
Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System - Dec 23rd, 2024 5:00 am
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device - Nov 18th, 2024 6:01 am
Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives - Nov 18th, 2024 6:00 am
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference - Oct 18th, 2024 6:00 am
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece - Oct 14th, 2024 3:00 pm
Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study - Sep 30th, 2024 6:00 am